|

PD(L)-1 inhibitor Clinical Trials

2 actively recruiting trials

Also known as: Nivolumab, Pembrolizumab

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University Cancer Hospital & Institute1
  • Fujian Medical University1

Indications

  • Cancer2
  • Collecting Duct Carcinoma1
  • Thyroid Neoplasms1
  • Thyroid Cancer1

Other2 trials

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.